SOPHION BIOSCIENCE A/S: Financial statements 2025
CVR: 10021065
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
SOPHION BIOSCIENCE A/S (CVR 10021065) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 102,112,000 and a net result of DKK 4,354,000 compared with DKK 39,127,000 the year before. That is a decrease of 14.6% compared with the year before. Equity in the 2025 report amounted to DKK 178,418,000. The solvency ratio was 75.1%. The company had 97 employees in the financial year.
- Gross Profit
- DKK 102,112,000
- Profit/Loss
- DKK 4,354,000
- Equity
- DKK 178,418,000
- Total Assets
- DKK 237,559,000
- Employees
- 97
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 102.1 mio. | 4.4 mio. | 178.4 mio. | 97 |
| 2024 | - | 119.6 mio. | 39.1 mio. | 192 mio. | 71 |
| 2023 | - | 113 t. | 28 mio. | 157 mio. | 57 |
| 2022 | - | 117.7 mio. | 44.4 mio. | 188.1 mio. | 48 |
| 2021 | - | 98.3 mio. | 36.3 mio. | 143.8 mio. | 41 |
Official annual report
How creditworthy is SOPHION BIOSCIENCE A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 3, 2025, Gustaf Peter Reinhold von Ehrenheim has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of December 3, 2025, Harald Høegh has joined the board of directors of SOPHION BIOSCIENCE A/S.
As of December 2, 2025, Gustaf Peter Reinhold von Ehrenheim has left the board of directors of SOPHION BIOSCIENCE A/S.
As of December 2, 2025, Harald Høegh has left the board of directors of SOPHION BIOSCIENCE A/S.
SOPHION BIOSCIENCE A/S has published its annual report for 2024. Gross profit came to DKK 119,621,000, and the net result was DKK 39,127,000.
About SOPHION BIOSCIENCE A/S
SOPHION BIOSCIENCE A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 2000. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IONS A/S and KR 228 A/S. The management consists of Michel Krall Jürgens. The board consists of Harald Høegh (chair), Eirik Lauglo, Gustaf Peter Reinhold von Ehrenheim and Peter Max. The company is owned by Sapphire Bioscience Holding ApS. The company has 86 employees (2026). In 2025, the company reported a gross profit of DKK 102,112,000 and a net result of DKK 4,354,000 compared with DKK 39,127,000 the year before. Equity in the 2025 report amounted to DKK 178,418,000.